Org. age Ohio . 711 - The Ohio State University

Byun, Y.; Narayanasamy, S.; Johnsamuel, J.; Bandyopadhyaya, A.K.; Tiwari, R.; Al- Madhoun, A.S.; Barth,
R.F.; Eriksson, S.; Tjarks, W. 3-Carboranyl Thymidine Analogues (3CTAs) and other Boronated Nucleosides for
Boron Neutron Capture Therapy; Anticancer Agents Med. Chem., 6, 127-144, 2006.
M. Salem and K. Werbovetz. Isoflavonoids and Other Compounds from Psorothamnus arborescens with
Antiprotozoal Activities, Journal of Natural Products, 69: 43-49, 2006.
P. Li, B. Pandit, D. Sackett, Z. Hu, J. Zink, J. Zhi, D. Freeman, R. Robey, K. Werbovetz, Lewis, and C. Li. A
thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Molecular
Cancer Therapeutics, 5: 450-456, 2006.
K. Werbovetz. Diamidines as Antitrypanosomal, Antileishmanial, and Antimalarial Agents, Current Opinion in
Investigational Drugs, 7: 147-157, 2006.
2006 Pharmaceutics
Au, J.L.-S., and Wientjes, M.G. Intravesical chemotherapy of superficial bladder cancer: optimization and novel
agents. In: Textbook on bladder cancer. Lerner, S., Schoenberg, M.P., and Sternberg, C., eds., Martin Dunitz
Publishers, 2006, pp. 341-352.
Fang L, Zhang G, Li C, Zheng X, Zhu L, Xiao JJ, Szakacs G, Nadas J, Chan KK, Wang PG, and Sun D.
Discovery of a Daunorubicin Analog that Exhibits Potent Antitumor Activity and Overcomes P-gp-mediated
Drug Resistance. J Med Chem, 49: 932-941, 2006.
Bekaii-Saab TS, Mortazavi AS, Hicks LG, Zalupski M, Pelley R, Chan KK, and Kraut EH. A Phase II Study of
Chloroquinoxaline Sulfonamide (CQS) in Patients with Metastatic Colorectal Carcinoma (MCRC) Investigational
New Drugs, 28 January, 2006.
Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, and Chan KK. Characterization of Decomposition Products and
Preclinical and Low Dose Clinical Pharmacokinetics of Decitabine (5-aza-2’-deoxycytidine) by a New LC-MS/MS
Quantification Method. Rapid Commun Mass Spectrom 20(7): 1117-1126, 2006.
O'Connor O, Smith EA, Toner LE, Feldstien J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, and
Chanan-Khan A. The Combination of the Proteasome Inhibitor Bortesomib and the Bcl-2 Antisense Molecule
Oblimersen Sensitizes Human B Cell Lymphomas to Cyclophosphamide. Clin Cancer Res 12(19): 2902-2911,
2006.
Segal S, Narayanan R, Dalton JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug
discovery. Expert Opinion in Investigational Drugs. 15(4):377-87, 2006.
Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising
therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion
in Investigational Drugs. 15(3):293-305, 2006.
Gao W, Johnston JS, Miller DD, Dalton JT. Inter-Species Differences in Pharmacokinetics and Metabolism of S-
3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide: The Role
of N-Acetyltransferase. Drug Metabolism and Disposition, 34(2):254-260, 2006.
Gao W, Wu Z, Bohl CE, Yang J, Miller DD, Dalton JT. Characterization of the In vitro Metabolism of Selective
Androgen Receptor Modulator (SARM) Using Human, Rat and Dog Liver Enzyme Preparations. Drug
Metabolism and Disposition, 34(2):243-253, 2006.
Wu D, Wu Z, Yang J, Nair VA, Miller DD, Dalton JT. Pharmacokinetics and metabolism of a selective androgen
receptor modulator (SARM) in rats–implication of molecular properties and intensive metabolic profile to
investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metabolism and
Disposition, 34(3):483-494, 2006.
Yang J, Bohl CE, Nair VA, Mustafa SM, Hong SS, Miller DD, Dalton JT. Preclinical pharmacology of a
nonsteroidal ligand for androgen receptor mediated imaging of prostate cancer. Journal of Pharmacology and
Experimental Therapeutics, 317(1):402-408, 2006.
49